



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

DPARKER@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3055

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

November 24, 2003

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313- 1450 on the date below:	
November 24, 2003	Date
David L. Parker	

MS DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Re: *U.S. Patent Application No: 10/673,671 Entitled "HIV-SPECIFIC T-CELL INDUCTION" by K. Jagannadha Sastry, et al.*  
*Our Ref: UTXC:561USC1*  
*Client Ref.: MDA97-036*

Sir :

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTXC:561USC1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,  
  
David L. Parker  
Reg. No. 32,165

DLP/kmv  
Encl.: As noted

25357830.1



**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:  
K. Jagannadha Sastry et al.**

Serial No.: 10/673,671

Filed: September 29, 2003

For: HIV-SPECIFIC T-CELL INDUCTION


### Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTXC:561USC1

**CERTIFICATE OF MAILING**  
**37 C.F.R 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

  
November 24, 2003

Date

David L. Parker

## INFORMATION DISCLOSURE STATEMENT

**MS DD**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTXC:561USC1.

This application is a divisional application of Serial No. 09/440,772, filed November 16, 1999 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/440,772.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 24, 2003



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
U.S. Patent Documents <i>See Page 1</i>		Filing Date: September 29, 2003	Group: Unknown
Foreign Patent Documents <i>See Page 2</i>		Other Art <i>See Page 2</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	3,791,932	2/12/74	Schuurs <i>et al.</i>	195	103.5R	1/27/72
	A2	3,949,064	4/6/76	Bornstein <i>et al.</i>	424	1	10/26/73
	A3	4,174,384	11/13/79	Ullman <i>et al.</i>	424	8	10/12/76
	A4	4,367,110	1/4/83	Yoshikawa	156	219	6/27/80
	A5	4,452,901	6/5/84	Gordon <i>et al.</i>	436	506	3/18/80
	A6	4,554,101	11/19/85	Hopp	260	112.5R	1/28/83
	A7	4,578,770	3/25/86	Mitani	364	571	6/10/83
	A8	4,596,792	6/24/86	Vyas	514	21	3/30/84
	A9	4,599,230	7/8/86	Milich <i>et al.</i>	424	89	3/9/84
	A10	4,601,903	7/22/86	Frasch	424	92	5/1/85
	A11	4,608,251	8/26/86	Mia	424	85	11/9/84
	A12	4,683,195	7/28/87	Mullis <i>et al.</i>	435	6	2/7/86
	A13	4,683,202	11/27/90	Mullis	435	91	10/25/85
	A14	4,690,915	9/1/87	Rosenburg	514	2	8/8/85
	A15	4,797,368	1/10/89	Carter <i>et al.</i>	435	320	3/15/85
	A16	4,800,159	1/24/89	Mullis <i>et al.</i>	435	172.3	12/17/86
	A17	4,883,750	11/28/89	Whiteley <i>et al.</i>	435	6	12/13/84
	A18	4,942,628	7/24/90	Rosen <i>et al.</i>	530	326	6/13/88
	A19	5,028,592	7/2/91	Lipton	514	18	8/5/88
	A20	5,128,319	7/7/92	Arlinghaus	514	12	9/20/89
	A21	5,139,941	8/18/92	Muzyczka <i>et al.</i>	435	172.3	10/25/91
	A22	5,142,025	8/25/92	Putney <i>et al.</i>	530	350	9/24/90

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

**INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)**

Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
U.S. Patent Documents <i>See Page 1</i>		Filing Date: September 29, 2003	Group: Unknown
Foreign Patent Documents <i>See Page 2</i>		Other Art <i>See Page 2</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A23	5,199,942	4/6/93	Gillis	604	4	9/26/91
	A24	5,221,605	6/22/93	Bard <i>et al.</i>	435	4	10/30/90
	A25	5,238,808	8/24/93	Bard <i>et al.</i>	435	4	10/24/85
	A26	5,279,721	1/18/94	Schmid	204	182.8	4/22/93
	A27	5,310,687	5/10/94	Bard <i>et al.</i>	436	518	11/4/91
	A28	5,620,896	4/15/97	Herrmann <i>et al.</i>	435	320.1	4/20/95
	A29	5,780,036	7/14/98	Chisari	424	189.1	4/4/95
	A30	5,958,895	9/28/99	Pachuk <i>et al.</i>	514	44	10/23/97
	A31	6,210,873	4/3/01	Sastry <i>et al.</i>	435	5	12/2/91
	A32	6,271,198	8-7-01	Braisted <i>et al.</i>	514	2	5-5-97

### Foreign Patent Documents


Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	320308	6/14/89	Europe			
	B2	329822	8/30/89	Europe			
	B3	2202328	9/21/88	Great Britain			
	B4	WO 88/10315	12/29/88	PCT			
	B5	WO 89/06700	7/27/89	PCT			
	B6	WO 90/07641	7/12/90	PCT			
	B7	WO 93/10816	6/10/93	PCT			
	B8	WO 93/19775	10/14/93	PCT			
	B9	WO 96/33734	10/31/96	PCT			

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

**INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)**

Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
 <b>List of Patents and Publications for Applicant's</b> <b>NOV 28 2003 INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant <b>K. Jagannadha Sastry et al.</b>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B10	0 267 802	5/18/88	Europe			
	B11	0 273 716	7/6/88	Europe			
	B12	0 284 587	9/28/88	Europe			
	B13	WO 89/03844	5/5/89	PCT			
	B14	WO 89/07112	8/10/89	PCT			
	B15	WO 93/10816	6/10/93	PCT			

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Agren <i>et al.</i> , "Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit," <i>J. Immunol.</i> 158:3936-3946, 1997.
	C2	Aichele <i>et al.</i> , "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> , 171:1815-1820, 1990.
	C3	Altman <i>et al.</i> , "Phenotypic analysis of antigen-specific T lymphocytes," <i>Science</i> , 274:94-96, 1996.
	C4	An and Whitton, "A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and T <sub>h</sub> epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen," <i>J. Virol.</i> , 71(3):2292-2302, 1997.
	C5	Barry <i>et al.</i> , "Protection against mycoplasma infection using expression-library immunization," <i>Nature</i> , 377:632-635, 1995.
	C6	Berzofsky, "Development of artificial vaccines against HIV using defined epitopes," <i>FASEB J.</i> , 5:2412-2418, 1991.
	C7	Bevan, "Stimulating killer cells," <i>Nature</i> , 342:478-479, 1989.
	C8	Bogedain <i>et al.</i> , "Specific cytotoxic T lymphocytes recognize the immediate-early transactivator ZTA of Epstein-Barr virus," <i>J. Virol.</i> , 69(8):4872-4879, 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

**INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)**

Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
<b>List of Patents and Publications for Applicant's</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <small>(Use several sheets if necessary)</small>		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Boyson <i>et al.</i> , The MHC class I genes of the rhesus monkey," <i>J. Immunol.</i> 156:4656-4665, 1996.
	C10	Braciale <i>et al.</i> , "Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes," <i>Immunol. Rev.</i> , 98:95-114, 1987.
	C11	Carmichael <i>et al.</i> , "Quantitative analysis of the human immunodeficiency virus Type I (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease," <i>J. Exp. Med.</i> , 177:249-256, 1993.
	C12	Casey <i>et al.</i> , "Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type I," <i>Virology</i> , 211(1):261-67, 1995.
	C13	Chopra <i>et al.</i> , "Cloning and expression of putative cytotoxic enterotoxin-encoding genes from <i>Aeromonas hydrophila</i> ," <i>Gene</i> 139:87-91, 1994.
	C14	Chopra <i>et al.</i> , Molecular and biochemical characterization of a heat-labile cytotoxic enterotoxin from <i>Aeromonas hydrophila</i> ," <i>Microbial Path.</i> 21:357-377, 1996.
	C15	Ciernik <i>et al.</i> , "Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes," <i>J. Immunol.</i> , 156:2369-2375, 1996.
	C16	Clerget-Raslain <i>et al.</i> , "Specificity of anti-peptide antibodies elicited against synthetic peptides mimicking conserved regions of HIV1 envelope glycoprotein," <i>Res. Virol.</i> , 142:423-438, 1991.
	C17	Dadaglio <i>et al.</i> , "Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes," <i>J. Immunol.</i> , 147:2302-2309, 1991.
	C18	Dai <i>et al.</i> , "Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8 <sup>+</sup> A24-restricted cytotoxic T lymphocytes," <i>J. Virol.</i> , 66:3151-3154, 1992.
	C19	De Rossi <i>et al.</i> , "Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism," <i>Virology</i> , 184:187-196, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Del Guercio <i>et al.</i> , "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses <i>in vivo</i> ," <i>Vaccine</i> 15:441-448, 1997.
	C21	Deres <i>et al.</i> , "In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> , 342:561-564, 1989.
	C22	Dupuis <i>et al.</i> , "Characterization of HLA-A*0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein," <i>J. Immunol.</i> , 155:2232-2239, 1995.
	C23	Falk <i>et al.</i> , "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Nat'l Acad. Sci. USA</i> , 90:12005-12009, 1993.
	C24	Falk <i>et al.</i> , "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Natl. Acad. Sci. USA</i> , 90:12005-12009, 1993.
	C25	Falk <i>et al.</i> , "Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells," <i>J. Exp. Med.</i> , 182:1005-1018, 1995.
	C26	Ferguson <i>et al.</i> , "Amino-acid residues involved in biological functions of the cytolytic enterotoxin from <i>Aeromonas hydrophila</i> ," <i>Gene</i> 156:79-83, 1995.
	C27	Ferguson <i>et al.</i> , "Hyperproduction, purification, and mechanism of action of the cytotoxic enterotoxin produced by <i>Aeromonas hydrophila</i> ," <i>Infect. Immun.</i> 65:4299-4308, 1997.
	C28	Flotte <i>et al.</i> , "An improved system for packaging recombinant adeno-associated virus vectors capable of <i>in vivo</i> transduction," <i>Gene Therapy</i> , 2:29-37, 1995.
	C29	Fuller and Haynes, "A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine," <i>AIDS Res. Hum. Retroviruses</i> , 11:1433-1441, 1994.
	C30	Gallichan and Rosenthal, "Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization," <i>J. Exp. Med.</i> 181:1879-1890, 1996.
	C31	Gao <i>et al.</i> , "Priming of influenza virus-specific cytotoxic T lymphocytes <i>vivo</i> by short synthetic peptides," <i>J. Immun.</i> , 147(10):3268-3273.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C32	Gorse <i>et al.</i> , "Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein," <i>Vaccine</i> , 13(13):1170-1179, 1995.
	C33	Goulder <i>et al.</i> , "Novel, cross-restricted, conserved and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type I infection," <i>AIDS Res. Hum. Retroviruses</i> , 12(18):1691-1698, 1996.
	C34	Gussow <i>et al.</i> , "Isolation, expression and the primary structure of <i>HLA-Cw1</i> and <i>HLA-Cw2</i> genes: evolutionary aspects," <i>Immunogenetics</i> , 25:313-322, 1987.
	C35	Imaoka <i>et al.</i> , "Nasal immunization of nonhuman primates with simian immunodeficiency virus p55 <sup>gag</sup> and cholera toxin adjuvant induces Th1/Th2 help for virus specific immune responses in reproductive tissues," <i>J. Immunol.</i> , 161:5952-5958, 1998.
	C36	Ishioka <i>et al.</i> , "Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes," <i>J. Immunol.</i> , 162:3915-3925, 1999.
	C37	Jassoy <i>et al.</i> , "Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex," <i>J. Immunol.</i> , 149:3113-3119, 1992.
	C38	Johnson <i>et al.</i> , "Identification of overlapping HLA class I-restricted cytotoxic epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation," <i>J. Exp. Med.</i> , 175:961-971, 1992.
	C39	Johnson <i>et al.</i> , "Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone," <i>J. Virol.</i> , 67(1):438-445, 1993.
	C40	Kast <i>et al.</i> , "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Nat'l Acad. Sci. USA</i> , 88:2283, 1991.
	C41	Keusch <i>et al.</i> , "Classification of enterotoxins on the basis of activity in cell culture," <i>J. Infect. Dis.</i> 131(1):58-63, 1973.

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



Form PTO-1449 (modified)

Atty. Docket No.  
UTXC:561USC1Serial No.  
10/673,671

**List of Patents and Publications for Applicant's  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
K. Jagannadha Sastry *et al.*Filing Date:  
September 29, 2003Group:  
Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C42	Klein <i>et al.</i> , "Kinetics of gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics," <i>J. Exp. Med.</i> , 181:1365-1372, 1995.
	C43	Koup <i>et al.</i> , "Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome," <i>J. Virol.</i> , 68:4650-4655, 1994.
	C44	Levy, "Pathogenesis of HIV infection," <i>Microbiol. Rev.</i> , 57:185-253, 1993.
	C45	Littaua <i>et al.</i> , "An HLA-C-restricted CD8+ cytotoxic T-Lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag," <i>J. Virol.</i> , 65:4051-4056, 1991.
	C46	Lu <i>et al.</i> , "Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice," <i>Virology</i> , 209:147-154, 1995.
	C47	Merino <i>et al.</i> , "Emerging Pathogens: <i>Aeromonas</i> spp.," <i>Int'l. J. Food. Microbiol.</i> 28:157-168, 1995.
	C48	Modrow <i>et al.</i> , "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions," <i>J. Virol.</i> 61:570-578, 1987.
	C49	Mortara <i>et al.</i> , "Type 1 CD4 <sup>+</sup> T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques," <i>J. Virol.</i> 73:4447-4451, 1999.
	C50	Musey <i>et al.</i> , "Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection," <i>New Engl. J. Med.</i> , 337(18):1267-1274, 1997.
	C51	Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells," <i>Curr. Top. Microbiol. Immunol.</i> , 158:97-129, 1992.
	C52	Nehete <i>et al.</i> , "A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans," <i>Vir. Immunol.</i> , 11(3):147-158, 1998.

EXAMINER:


DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

NOV 28 2003

Form PTO-1449 (modified)

Atty. Docket No.  
UTXC:561USC1Serial No.  
10/673,671

## List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
K. Jagannadha Sastry *et al.*Filing Date:  
September 29, 2003Group:  
Unknown

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 2

## Other Art

See Page 2

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C53	Nehete <i>et al.</i> , "Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals," <i>J. Clin. Immunol.</i> , 16(2):115-124, 1996.
	C54	Nehete <i>et al.</i> , "Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160," <i>AIDS Res. Hum. Retroviruses</i> , 9:235-240, 1993.
	C55	Nehete <i>et al.</i> , "Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus," <i>Vir. Immunol.</i> , 11(3):119-129, 1998.
	C56	Nehete <i>et al.</i> , "Studies on <i>in vivo</i> induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from V3 loop region of HIV-1 IIIB gp120," <i>Cell. Immunol.</i> , 160:217, 1995.
	C57	Nehete <i>et al.</i> , "Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1 <sub>IIIB</sub> ," <i>AIDS</i> 9:567-572, 1995.
	C58	Nehete <i>et al.</i> , "Use of helper T cell-inducing peptides from conserved regions in HIV-1 <i>env</i> in a noncovalent mixture with a CTL-inducing V3-loop peptide for <i>in vivo</i> induction of long-lasting systemic CTL response," <i>Vir. Immunol.</i> , 7(4):189-197, 1994.
	C59	Pantaleo <i>et al.</i> , "Major expansion of CD8 <sup>+</sup> T cells with a predominant V $\beta$ usage during the primary immune response to HIV," <i>Nature</i> , 370:463-467, 1994.
	C60	Peterson <i>et al.</i> , "Cholera toxin B subunit activates arachidonic acid metabolism," <i>Infect. Immunol.</i> 67:794-799, 1999.
	C61	Picard <i>et al.</i> , "A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity," <i>J. Acquired Immune Defic. Syndr.</i> , 5:539-546., 1992.
	C62	Pontesilli <i>et al.</i> , "HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals," <i>Clin. Exp. Immunol.</i> , 100:419-424, 1995.
	C63	Porgador <i>et al.</i> , "Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development <i>in vivo</i> ," <i>J. Immunol.</i> 158:834-841, 1997.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
UTXC:561USC1Serial No.  
10/673,671

## List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
K. Jagannadha Sastry *et al.*Filing Date:  
September 29, 2003Group:  
Unknown

## U.S. Patent Documents

See Page 1

## Foreign Patent Documents

See Page 2

## Other Art

See Page 2

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C64	Roos <i>et al.</i> , "T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects," <i>J. Infect. Dis.</i> , 171:531-536, 1995.
	C65	Rosenberg <i>et al.</i> , <i>Science</i> , "Vigorous HIV-1-specific CD4 <sup>+</sup> T cell responses associated with control of viremia," 278:1447-1450, 1997.
	C66	Rowland-Jones <i>et al.</i> , "HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant," <i>Lancet</i> , 341:860-861, 1993.
	C67	Rowland-Jones <i>et al.</i> , "HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women," <i>Nature Med.</i> , 1:59-64, 1995.
	C68	Sarkar <i>et al.</i> , "Studies on <i>in vivo</i> induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16," <i>Viral Imm.</i> , 8:165-174, 1995.
	C69	Sastry and Arlinghaus, "Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein," <i>AIDS</i> , 5:699-707, 1991.
	C70	Sastry <i>et al.</i> , "Rapid <i>in vivo</i> induction of HIV-specific CD8 <sup>+</sup> cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120," <i>Virology</i> , 188:502-509, 1992.
	C71	Schendel <i>et al.</i> , "Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides," <i>J. Immunol.</i> , 149:2406-2416, 1992.
	C72	Schrier <i>et al.</i> , "T cell recognition of HIV synthetic peptides in a natural infection," <i>J. Immunol.</i> , 142:1166-1176.
	C73	Sedegah <i>et al.</i> , "Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein," <i>Immunology</i> , 91:9866-9870, 1994.
	C74	Takahashi <i>et al.</i> , "Specific lysis of human immunodeficiency virus type 1-infected cells by a HLC-A3.1-restricted CD8 <sup>+</sup> cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein," <i>Proc. Natl. Acad. Sci. USA</i> , 88:10277-10281, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C75	Ulmer <i>et al.</i> , "Heterologous protection against influenza by injection of DNA encoding a viral protein," <i>Science</i> , 259:1745-1749, 1993.
	C76	Unanue & Cerottini, "Antigen presentation," <i>FASEB J.</i> 3:2496-2502, 1989.
	C77	van den Eynde <i>et al.</i> , "A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma," <i>J. Exp. Med.</i> , 182:689-698, 1995.
	C78	Wang <i>et al.</i> , "Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four <i>plasmodium falciparum</i> DNA plasmids," <i>Infec. Imm.</i> , 66(9):4193-4202, 1998.
	C79	Xiang <i>et al.</i> , "Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus," <i>Virology</i> , 199:132-140, 1994.
	C80	Xu <i>et al.</i> , "Role of a cytotoxic enterotoxin in <i>Aeromonas</i> -mediated infections: development of transposon and isogenic mutants," <i>Infect. Immun.</i> 66:3501-3509, 1998.
	C81	Yamada <i>et al.</i> , "Incidence and clinical symptoms of <i>Aeromonas</i> -associated travellers' diarrhoea in Tokyo," <i>Epidemiol. &amp; Infect.</i> 119:121-126, 1997.
	C82	Yasutomi <i>et al.</i> , "Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys," <i>J. Virol.</i> , 70:678-681, 1996.
	C83	Yokoyama <i>et al.</i> , "DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection," <i>J. Virol.</i> , 69(4):2684-2688, 1995.
	C84	Zemmour and Parham, "HLA class I nucleotide sequences, 1992," <i>Immunogenetics</i> , 37:239-250, 1993.

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)